RT Journal Article
SR Electronic
T1 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3771
OP 3774
VO 36
IS 7
A1 INUI, TOSHIO
A1 KATSUURA, GORO
A1 KUBO, KENTARO
A1 KUCHIIKE, DAISUKE
A1 CHENERY, LESLYE
A1 UTO, YOSHIHIRO
A1 NISHIKATA, TAKAHITO
A1 METTE, MARTIN
YR 2016
UL http://ar.iiarjournals.org/content/36/7/3771.abstract
AB Background/Aim: Gc protein-derived macrophage-activating factor (GcMAF) has various functions as an immune modulator, such as macrophage activation, anti-angiogenic activity and anti-tumor activity. Clinical trials of second-generation GcMAF demonstrated remarkable clinical effects in several types of cancers. Thus, GcMAF-based immunotherapy has a wide application for use in the treatment of many diseases via macrophage activation that can be used as a supportive therapy. Multiple sclerosis (MS) is considered to be an autoimmune disorder that affects the myelinated axons in the central nervous system (CNS). This study was undertaken to examine the effects of second-generation GcMAF in a patient with MS. Results: This case study demonstrated that treatments of GcMAF in a patient with MS have potent therapeutic actions with early beneficial responses, especially improvement of motor dysfunction. Conclusion: GcMAF shows therapeutic potency in the treatment of MS.